Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework

ABSTRACTOptimal pharmacokinetic (PK) properties of therapeutic monoclonal antibodies (mAbs) are essential to achieve the desired pharmacological benefits in patients. To accomplish this, we followed an approach comprising structure-based mAb charge engineering in conjunction with the use of relevant...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Romain Ollier (Egilea), Aline Fuchs (Egilea), Florence Gauye (Egilea), Katarzyna Piorkowska (Egilea), Sébastien Menant (Egilea), Monisha Ratnam (Egilea), Paolo Montanari (Egilea), Florence Guilhot (Egilea), Didier Phillipe (Egilea), Mickael Audrain (Egilea), Anne-Laure Egesipe (Egilea), Damien Névoltris (Egilea), Tamara Seredenina (Egilea), Andrea Pfeifer (Egilea), Marie Kosco-Vilbois (Egilea), Tariq Afroz (Egilea)
Formatua: Liburua
Argitaratua: Taylor & Francis Group, 2023-12-01T00:00:00Z.
Gaiak:
Sarrera elektronikoa:Connect to this object online.
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak